From GlobeNewswire: 2025-02-25 06:00:00

Integra LifeSciences reported a 11.5% increase in revenues to $442.6 million in Q4 2024, with GAAP earnings per diluted share at $0.25. For full-year 2024, revenues were $1,610.5 million, a 4.5% increase, but GAAP earnings per diluted share were $(0.09). The company also provided 2025 revenue guidance of $1,650-1,715 million and adjusted earnings per diluted share of $2.41-2.51.

Key business highlights for 2024 include the appointment of Mojdeh Poul as President & CEO, strong demand for leading brands, and successful integration of the Acclarent acquisition. The company is focused on enhancing quality management systems, making critical investments in capacity, and expanding its international footprint and portfolio.

In Q4 2024, reported revenues were $442.6 million, a 11.5% increase from Q4 2023. GAAP net income was $19.4 million, with adjusted EBITDA at $104.9 million. For the full-year 2024, reported revenues were $1,610.5 million, with GAAP net income of $(6.9) million. Adjusted net income for 2024 was $196.9 million.

Integra’s 2025 revenue guidance expects reported growth of 2.4-6.5%, with organic growth of 1.0-5.0%. Adjusted earnings per diluted share are projected to be $2.41-2.51. For Q1 2025, reported revenues are expected to be $375-385 million, with organic growth of -6.2% to -3.5%.

The Company generated cash flow from operations of $129.4 million in 2024. Net debt at the end of the year was $1.5 billion, with total liquidity of approximately $1.2 billion. Adjusted free cash flow conversion for the year was 12.7%, reflecting the impact of cash special charges on adjusted earnings measures.



Read more at GlobeNewswire:: Integra LifeSciences Reports Fourth Quarter and Full-Year